A, U. S. K. S. K. A. J. M. R. H. H. T. Z. Y. S. S. W. (2022). Prospect of Anterior Gradient 2 homodimer inhibition via repurposing FDA-approved drugs using structure-based virtual screening. Molecular Diversity, 26(3), . https://doi.org/10.1007/s11030-021-10263-x
Chicagoスタイル(17版)引用形式A, Ullah S.; Khan S.U.; Khan A.; Junaid M.; Rafiq H.; Htar T.T.; Zhao Y.; Shah S.A.A.; Wadood. "Prospect of Anterior Gradient 2 Homodimer Inhibition via Repurposing FDA-approved Drugs Using Structure-based Virtual Screening." Molecular Diversity 26, no. 3 (2022). https://doi.org/10.1007/s11030-021-10263-x.
MLA(8版)引用形式A, Ullah S.; Khan S.U.; Khan A.; Junaid M.; Rafiq H.; Htar T.T.; Zhao Y.; Shah S.A.A.; Wadood. "Prospect of Anterior Gradient 2 Homodimer Inhibition via Repurposing FDA-approved Drugs Using Structure-based Virtual Screening." Molecular Diversity, vol. 26, no. 3, 2022, https://doi.org/10.1007/s11030-021-10263-x.